The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

"Our revenue volatility is largely in the past as COVID-related uncertainties have diminished," Pfizer's finance chief David ...

U.S. health experts anticipate a smaller wave of COVID-19 cases this winter, potentially impacting Pfizer's non-COVID ...

Big Pharma often turns to NFL games to hawk their blockbuster treatments, but drug makers have typically been hesitant to ...

Paxlovid, one of the most well-known treatments ... Not only does it have numerous side effects, but it can also have serious and sometimes life-threatening interactions with other medications ...

High-risk groups in particular should get tested, Offit added, so that they can receive antiviral Paxlovid to limit the severity of their infection. “Although the pandemic is over, I think we have to ...

Wen Shuhao helped speed up the development of Pfizer’s Covid oral drug, Paxlovid. Now the cofounder ... In the first half of 2024, the most recent financial period publicly available, Xtalpi ...

Pfizer benefited from the pandemic. Sales of its COVID-19 vaccine (Comirnaty) and treatment (Paxlovid) totaled over $56 billion in 2022, over half of the company's revenue that year. However ...

An oncology-focused Pfizer is poised to grow over the coming years. Abundant (and growing) earnings protect the dividend despite an abnormally high yield. The stock's valuation signals that the ...

Follow-up rates were similar in the treated and untreated groups, with slightly more adverse events demonstrated in the Paxlovid vs control group. Researchers conducted a retrospective electronic ...